Champions OncologyCSBR -0.98%64 Piotroski F-Score is 4 as of Jun. 25, 2026, which is at its 10-year median of 4.00. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,342 Biotechnology companies, Champions Oncology ranks better than 74.22% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Champions Oncology has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Champions Oncology's Piotroski F-Score or its related term are showing as below:
CSBR'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 9
Current: 4
During the past 13 years, the highest Piotroski F-Score of Champions Oncology was 9. The lowest was 1. And the median was 4.
Champions Oncology (NAS:CSBR) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Champions Oncology Piotroski F-Score Related Terms
Champions Oncology Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBR vs ANVS, HYFT, GANX: Piotroski F-Score Comparison
For the Biotechnology subindustry, Champions Oncology's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Champions Oncology's current Net Income (TTM) was -2.28.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Champions Oncology's return on assets of this year was -0.07447677. Champions Oncology's return on assets of last year was 0.23992982.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Champions Oncology's gearing of this year was 0.11059911. Champions Oncology's gearing of last year was 0.1870714.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Champions Oncology's current ratio of this year was 0.97620545. Champions Oncology's current ratio of last year was 0.99129341.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Champions Oncology's number of shares in issue this year was 13.887. Champions Oncology's number of shares in issue last year was 14.365.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Champions Oncology's gross margin of this year was 0.45875328. Champions Oncology's gross margin of last year was 0.51584714.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Champions Oncology's asset turnover of this year was 1.89192543. Champions Oncology's asset turnover of last year was 2.18729234.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
0
+
1
+
1
+
0
+
1
+
0
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Champions Oncology has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Champions Oncology (CSBR) has a Piotroski F-Score of 4 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Champions Oncology and its competitors. This is near median its historical median of 4.00. Over the past decade, Champions Oncology's Piotroski F-Score has ranged from 1.00 to 9.00. According to the industry distribution chart, Champions Oncology ranks #346 out of 1342 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Champions Oncology's Piotroski F-Score too high?
Champions Oncology's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. Champions Oncology's value of 4 is 33.3% above this industry median. Based on the distribution chart, Champions Oncology ranks #346 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Piotroski F-Score compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #346 out of 1342 companies for Piotroski F-Score. This puts Champions Oncology in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Champions Oncology's value of 4 is 33.3% above this benchmark. Historically, Champions Oncology's own Piotroski F-Score has ranged from 1.00 to 9.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Champions Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Champions Oncology's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Champions Oncology and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Champions Oncology's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.14 — trading 7.3% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Piotroski F-Score is 4 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.14 is trading 7.3% below its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: $6.62 vs. price of $6.14 (7.3% below fair value)
Industry Position: 33.3% above the Biotechnology median (#346 of 1342)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
